ical and mycologic examination revealed absence of infection in 19 of the 20 patients in the miconazole group, 10 of the 20 in the placebo group and 15 of the 20 in the tolnaftate group.

At the 6-week follow-up 19 (95%) of the 20 patients in the miconazole group remained free of infection, whereas only 2 (10%) of the 20 in the placebo group and 13 (65%) of the 20 in the tolnaftate group remained free of infection.

Discussion

Miconazole was effective in clearing dermatophyte infection of the feet in 95% of patients, and there were no recurrences in the following 6 weeks.

The rather surprising initial response to the placebo may be explained by the presence of ethylene glycol esters in the cream base, since ethylene glycol has some antimicrobial activity. The hygienic improvement undoubtedly added to the placebo effect. The high rate of relapse and the continuing presence of fungal elements indicate the temporary nature of this effect.

The inclusion of tolnaftate in the study allowed conclusions as to the relative efficacy of the two agents. As expected, significant (P < 0.03) and lasting clinical improvement was seen in the tolnaftate-treated sites as compared with the placebo-treated sites. However, comparison of the results with the two active agents showed a significant difference (P

< 0.05) in favour of miconazole.

Miconazole, as demonstrated by this study, appears to live up to the expectations generated by previous reports¹⁻³ and should prove a very useful agent in the treatment of superficial fungal infections of the skin.

All materials for the study were provided by McNeil Laboratories (Canada) Limited.

References

- SVEJGAARD E: Double-blind trial of miconazole in dermatomycosis. Acta Derm Venereol (Stockh) 53: 497, 1973
- 2. BOTTER AA: Topical treatment of nail and skin infections with miconazole, a new broad-spectrum antimycotic. Mykosen 14: 187, 1971
- MANDY SJ, GARROTT TC: Miconazole treatment for severe dermatophytoses. JAMA 230: 72, 1974

Massive aspiration of talcum powder by an infant

FERNANDE BROUILLETTE, MD; MICHEL L. WEBER, MD, FRCP[C]

Talcum powder, which contains mostly magnesium silicate, is widely used for the routine care of infants in the home.

At least 24 cases of talcum powder aspiration have been described in the literature. The principal data about these cases and the one we have encountered are summarized in Table I. Most of the children were older than 6 months, and those old enough to play with the container were considered at risk. The mortality was 20%; of the 17 patients treated with steroids 2 died (12%), whereas of the 8 children not treated with steroids 3 (38%) died.

Our case, one of severe pneumonia due to talcum powder aspiration in a 1-month-old infant, the youngest patient we are aware of, is reported below.

Case report

On Sept. 14, 1977 a 1-month-old girl who had been born prematurely was found in her crib in respiratory distress. She was covered with talcum powder, which had been poured into

From the department of pediatrics, University of Montreal and hôpital Sainte-Justine, Montreal

Reprint requests to: Dr. Michel L. Weber, Hôpital Sainte-Justine, 3175 chem. Côte Ste-Catherine, Montreal, PQ H3T 1C5 her mouth and nose and onto her body by her 3-year-old brother.

The baby arrived at a nearby hospital in cardiorespiratory arrest. Resuscitative measures included endotracheal intubation, positive pressure ventilation, intracardiac administration of epinephrine, and intravenous administration of bicarbonate and hydrocortisone. Approximately 40 minutes after these measures were started she began to breathe spontaneously and to move her limbs, and was then transferred to Sainte-Justine Hospital.

At the time of admission to our hospital, 3 hours after the accident, the baby was spontaneously breathing

100% oxygen through an endotracheal tube at a rate of 30/min, and her colour was satisfactory. She was moving all four limbs. Intercostal retractions and numerous wheezes were noted. Talcum powder was present in the nose and mouth. A specimen of arterial blood with the patient breathing 100% oxygen showed that the partial pressure of oxygen was 45 mm Hg, the partial pressure of carbon dioxide 31 mm Hg, the pH 7.12 and the base excess -17 meq/L. The hemoglobin value was 8.4 g/dL and the leukocyte count $27.2 \times 10^9/L$ (including 11%neutrophils and 12% band forms). Roentgenography of the chest demon-

Authors	No. of patients	Age	Treatment	Outcome
Molnar, Nathenson and Edberg ⁷	1	22 months	No steroids	Died .
lenkins ⁵	1	14 months	No steroids	Died
Hughes and Kalmer ⁴	1	14 months	Steroids	Survived
Cless and Anger ¹	1	10 months	No steroids	Died
Lund and Feldt-Rasmussen ⁶	1	24 months	Steroids	Survived
Gould and Barnardo ²	1	7 years	Steroids	Survived
Tortorolo and Romano ⁹	3	7 months	Steroids	Survived
		12 months	Steroids	Survived
		9 months	Steroids	Died
Gouvea and colleagues ³	13	5: < 1 year 4: 1 to 2 years	Steroids in 8 cases, bron- chial washing	12 survived; 1 died (with steroid
		4: > 4 years	in 11	therapy)
Pfenninger and D'Apuzzo ^s	2	7 months	Steroids and bronchial washing	Survived
		13 months	Steroids	Survived
Brouillette and Weber (present case)	1	1 month	Steroids	Survived




FIG. 1—Bilateral pulmonary infiltrations in 1-month-old infant after aspiration of talcum powder (endotracheal tube has temporarily slipped into right mainstem bronchus).

strated bilateral infiltrations (Fig. 1).

The baby was given mechanical ventilation, oxygen, nafcillin, gentamicin, hydrocortisone and physical therapy to the chest. The alveolar-arterial difference in oxygen tension remained high for 72 hours and then started to decrease. The clinical course was similar to that of severe bronchiolitis. The baby was successfully weaned from the ventilator and the nasotracheal tube was removed 6 days after admission. She was discharged from hospital 6 days later, without any apparent sequelae.

Discussion

Talcum powder is usually not considered harmful by parents and physicians, but in view of the high mortality associated with its aspiration its presence in the home should be regarded as potentially hazardous. Since it is not essential to the routine care of infants its use should be discouraged, or at least parents should be strongly advised not to leave containers within the reach of children, and should be told about the serious and even fatal consequences of its inhalation.

In cases of talcum powder aspiration steroid therapy should probably be given in addition to the usual therapy for respiratory insufficiency. Bronchial washing may also be useful in severe cases, but this is a potentially dangerous procedure. The authors who have reported the use of this approach have not presented sufficient technical details for an evaluation of its value and dangers.^{3,8}

We are grateful to Dr. Allyson Eddy, who reviewed the manuscript.

References

- CLESS D, ANGER R: Erstickungstod durch Aspiration von Kinderpuder. Kinderaertzl Prax 22: 506, 1954
- GOULD SR, BARNARDO ED: Respiratory distress after talc inhalation. Br J Dis Chest 66: 230, 1972
- 3. GOUVEA FP, GONSALVES PE, LEBRUN E, et al: Aspiração aguda de talco e outros pós: terapéutica por lavagem brónquica. Rev Hosp Clin Fac Med Sao Paulo 21: 49, 1966
- 4. HUGHES WT, KALMER T: Massive talc aspiration. Successful treatment with dexamethasone. Am J Dis Child 111: 653, 1966
- Jenkins MQ: Poisoning of the month. Dusting powder inhalation. J SC Med Assoc 59: 62, 1963
- Lund JS, Feldt-Rasmussen M: Accidental aspiration of talc. Report of a case in a two-year-old child. Acta Paediatr Scand 58: 295, 1969
- MOLNAR JJ, NATHENSON G, EDBERG S: Fatal aspiration of talcum powder by a child. Report of a case. N Engl J Med 266: 36, 1962
- 8 PFENNINGER J, D'APUZZO V: Powder aspiration in children: report of two cases. Arch Dis Child 52: 157, 1977
- TORTOROLO G, ROMANO C: Pneumopatia acuta da inalazione di talco. Minerva Nipiol 16: 15, 1966

The Royal College of Physicians and Surgeons of Canada

Examinations

The examinations of the Royal College are held in September of each year. Candidates wishing to sit for the examinations should note the following:

- 1. Every candidate for admission to the examinations must submit an application for assessment of training.
- 2. Candidates in training in Canada should apply for preliminary assessment of training at least one year before the date on which they expect to sit for the examinations, that is to say not later than September 1st of the preceding year. Candidates who have had training outside of Canada should submit their initial application for assessment at least eighteen months before they expect to sit for the examinations, that is by March 1st of the preceding year. Only candidates whose assessment of credentials is complete will be accepted to sit for the examinations.
- 3. Candidates who desire to sit for an examination, having complied with the above requirement of preliminary assessment of training, must notify the College in writing of their intent before February 1st of the year of the examination. Upon receipt of this notice of intent, the evaluation of the candidate's performance during training will be added to the previously completed assessment of credentials. Each candidate will then receive notification as to eligibility together with an application form for admission to the examination which he will complete and return.
- 4. The following documents may be obtained from the College office:
- (a) Application forms for assessment of training.
- (b) General Information booklet on training requirements and examinations.
- (c) Specific requirements for training and regulations relating to the examinations of each specialty. Requests should indicate the specialty or specialties of interest to the applicant.
- (d) Listing of specialty training programmes in Canada accredited by the College.
 - 5. Address all enquiries to:

Division of Training and Evaluation ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA 74 Stanley Avenue Ottawa, Ontario K1M 1P4 Tel.: (613) 746-8177